HC Wainwright & Co. Maintains Buy on Abeona Therapeutics, Lowers Price Target to $18
Benzinga Newsdesk 3 hours ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Abeona Therapeutics (NASDAQ:ABEO) with a Buy and lowers the price target from $20 to $18.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Abeona Therapeutics (NASDAQ:ABEO) with a Buy and lowers the price target from $20 to $18.